CBM-Possible Beneficiary Of Sovaldi Launch
Growth, Healthcare, Biotech
Seeking Alpha Analyst Since 2012
Cambrex is an active pharmaceutical ingredients manufacturer. The company is making significant capital investments for key growth projects. Cambrex signed a non-exclusive manufacturing agreement with a customer in 2012 for production of "commercial launch material for a large new product candidate, including Phase 3". In Q3 2013, custom development revenues grew by over 500%. It is speculated that the drug involved is Gilead's Sovaldi. Although this is not certain, Cambrex's stock is conservatively valued, and I strongly maintain that Sovaldi revenues will be significantly higher than Street expectations. However, even if Sovaldi is the drug, the nature of the agreement with Gilead is not known. Cambrex is going to report Q4 2013 results around 2/11. Given the revenue contribution of this manufacturing agreement to Cambrex, it may be required to disclose the other party. All this being said, I find this stock very interesting at its current level. Len
Disclosure: I am long CBM, GILD.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.